| MeSH term | MeSH ID | Detail |
|---|---|---|
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
Total
3
Norethindrone
Norethindrone is a lipid of Sterol Lipids (ST) class. Norethindrone is associated with abnormalities such as Endometriosis, site unspecified, Wiskott-Aldrich Syndrome and Estrogenic effect. The involved functions are known as Hemorrhage, Phosphorylation, Apoptosis, DNA Repair and Cell Cycle. Norethindrone often locates in Blood, Back, Body tissue, Nucleolar and Human tissue. The associated genes with Norethindrone are MMP gene, NR3C1 gene and Genes, Reporter. The related lipids are Steroids, 4,17 beta-dihydroxy-4-androstene-3-one, 4-estren-3,17-diol and Estranes.
Cross Reference
Introduction
To understand associated biological information of Norethindrone, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Norethindrone?
Norethindrone is suspected in Endometriosis, site unspecified, Estrogenic effect and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Norethindrone
PubChem Associated disorders and diseases
What pathways are associated with Norethindrone
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Norethindrone?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Norethindrone?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Norethindrone?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Norethindrone?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Norethindrone?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with Norethindrone
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Lachnit-Fixson U and Aydinlik S | [New cycle-stabilizing contraceptive agent (Ediwal)]. | 1976 | Med Monatsschr | pmid:979900 |
| Norethindrone--the "minipill". | 1973 | Med Lett Drugs Ther | pmid:4712978 | |
| Norinyl 1+80 and Ortho-Novum 1/80. | 1969 | Med Lett Drugs Ther | pmid:5778361 | |
| Ortho-Novum 10/11--a new "bi-phasic" oral contraceptive. | 1982 | Med Lett Drugs Ther | pmid:7121396 | |
| Three new combination oral contraceptives: Seasonique, Loestrin 24 Fe, and Yaz. | 2006 | Med Lett Drugs Ther | pmid:17001297 | |
| Mehring W | [The effect of ovulation inhibitors on the vaginal picture and the portio epithelium]. | 1965 | Med Klin | pmid:5870226 |
| Boon J et al. | Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. | 2003 | Maturitas | pmid:12963171 |
| Kurtay G et al. | A comparison of effects of sequential transdermal administration versus oral administration of estradiol plus norethisterone acetate on serum NO levels in postmenopausal women. | 2006 | Maturitas | pmid:16325022 |
| Campagnoli C et al. | Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. | 1994 | Maturitas | pmid:7935029 |
| Lundström E et al. | Digitized assessment of mammographic breast density--effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. | 2011 | Maturitas | pmid:21958943 |
| Perry W and Wiseman RA | Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: effect on lipids, coagulation factors, haematology and biochemistry. | 2002 | Maturitas | pmid:12065175 |
| Pedersen NG et al. | Progestins used in hormonal replacement therapy display different effects in coronary arteries from New Zealand white rabbits. | 2004 | Maturitas | pmid:15531126 |
| Piccioni P et al. | Hormonal replacement therapy after stem cell transplantation. | 2004 | Maturitas | pmid:15531129 |
| Gotfredsen A et al. | Effect of natural oestrogen/gestagen therapy on uric acid metabolism in post-menopausal women. | 1983 | Maturitas | pmid:6348486 |
| Samsioe G et al. | One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. | 2007 | Maturitas | pmid:17317046 |
| Eiken P and Kolthoff N | Compliance with long-term oral hormonal replacement therapy. | 1995 | Maturitas | pmid:8538490 |
| Abdalla HI et al. | Sex steroid replacement in post-menopausal women: effects on thyroid hormone status. | 1987 | Maturitas | pmid:3037279 |
| Li C et al. | Effects of norethisterone acetate addition to estradiol in long term HRT. | 2000 | Maturitas | pmid:11006501 |
| Simsek T et al. | Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system. | 2002 | Maturitas | pmid:12161049 |
| Volpe A et al. | Benefits and risks of different hormonal replacement therapies in post-menopausal women. | 1986 | Maturitas | pmid:3033444 |
| Bjarnason K et al. | Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. | 1999 | Maturitas | pmid:10515673 |
| Fink BJ | Endometrial changes after long-term use of continuous oestrogen and cyclic progestogen. | 1984 | Maturitas | pmid:6738374 |
| Bruhat M et al. | Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study. | 2001 | Maturitas | pmid:11731187 |
| Sporrong T et al. | A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy. | 1989 | Maturitas | pmid:2593864 |
| Polisseni AF et al. | Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study. | 2013 | Maturitas | pmid:23201326 |
| Stadberg E et al. | Bioavailability of norethisterone acetate alone and in combination with estradiol administered in single or multiple oral doses to postmenopausal women. | 1999 | Maturitas | pmid:10585174 |
| Riis BJ et al. | Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. | 1988 | Maturitas | pmid:3041248 |
| Gordan GS | Prevention of bone loss and fractures in women. | 1984 | Maturitas | pmid:6392827 |
| Nahas-Neto J et al. | Evaluation of mammographic density and (99m)Tc-sestamibi scintimammographic uptake in postmenopausal women on hormone replacement therapy. | 2006 | Maturitas | pmid:15941630 |
| Grasso A et al. | Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy. | 1982 | Maturitas | pmid:6285153 |
| Dahmoun M et al. | Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT. | 2004 | Maturitas | pmid:15474755 |
| Loh FH et al. | The efficacy of two dosages of a continuous combined hormone replacement regimen. | 2002 | Maturitas | pmid:11836043 |
| Magos AL et al. | Endometrial and menstrual response to subcutaneous oestradiol and testosterone implants and continuous oral progestogen therapy in post-menopausal women. | 1985 | Maturitas | pmid:4079826 |
| Meuwissen JH et al. | Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. | 1995 | Maturitas | pmid:7752949 |
| Frenkel Y et al. | Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. | 1994 | Maturitas | pmid:7877518 |
| Riis BJ and Christiansen C | Post-menopausal bone loss: effects of oestrogens and progestogens. A review. | 1986 | Maturitas | pmid:3553863 |
| Gambacciani M et al. | Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. | 2003 | Maturitas | pmid:12590012 |
| Glusa E et al. | Mechanisms of relaxation of rat aorta in response to progesterone and synthetic progestins. | 1997 | Maturitas | pmid:9522326 |
| Tuppurainen M et al. | Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up. | 2010 | Maturitas | pmid:20547017 |
| Peverill RE et al. | Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. | 2006 | Maturitas | pmid:16368469 |
| Popp AW et al. | Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. | 2006 | Maturitas | pmid:16368472 |
| Ylöstalo P et al. | Serum bile acids and lipids during treatment of climacteric symptoms with natural oestrogen--progestin combinations. | 1981 | Maturitas | pmid:7253932 |
| Biglia N et al. | Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens. | 2003 | Maturitas | pmid:12927315 |
| Gambacciani M et al. | Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. | 2008 | Maturitas | pmid:18063490 |
| Dören M and Schneider HP | Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. | 1996 | Maturitas | pmid:8905600 |
| Taner MZ et al. | Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study. | 2006 | Maturitas | pmid:15978753 |
| Marslew U et al. | Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. | 1994 | Maturitas | pmid:7799829 |
| Need AG et al. | Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis. | 1986 | Maturitas | pmid:3574140 |
| Obel EB et al. | A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. | 1993 | Maturitas | pmid:8429800 |
| Hellberg D and Nilsson S | Comparison of a triphasic oestradiol/norethisterone acetate preparation with and without an oestriol component in the treatment of climacteric complaints. | 1984 | Maturitas | pmid:6429481 |